NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today a strategic partnership to provide a new platform technology for ADDF ACCESS. ADDF ACCESS is an open access database that provides a network of contract research organizations (CROs), drug development consultants and educational resources focused for diseases of the central nervous system (CNS). By leveraging OnDeckBiotech's cutting-edge technology, ADDF ACCESS will increase the efficiency of contracting drug development services by scientists in academia and small biotechnology companies.
"This is an exciting opportunity to leverage the OnDeck technology and a dedicated development team to improve the functionality of ADDF ACCESS," said Howard Fillit, MD, executive director and chief science officer, ADDF. "The new platform will streamline the process of identifying and contracting with CROs that have pharmaceutical development expertise for challenging CNS diseases. This type of expertise is critical to the success of translational CNS research programs in academia and small biotechnology companies."
"It's not uncommon for a study director to spend weeks searching for and evaluating vendors experienced with a particular model. These costly delays are an unnecessary distraction for scientific teams and any misstep can compromise an otherwise promising program" said Cliff Culver, CEO and founder, OnDeckBiotech. "We have seen significant savings of time and reduced administrative cost for both sponsors and vendors on the platform and we are confident these improvements have a positive impact on research efficiency."
ADDF ACCESS users will see improved functionalities across the ADDF ACCESS platform, including direct communication with CROs and consultants, a suite of project management tools and educational resources focused for drug development for CNS diseases.
The new ADDF ACCESS platform powered by OnDeckBiotech is set to go live and be fully functional in early September in conjunction with ADDF's 15th International Conference on Alzheimer's Drug Discovery in Jersey City, NJ.
About the Alzheimer's Drug Discovery Foundation (ADDF)
The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's diseases, related dementias and cognitive aging. The ADDF has granted more than $65 million to fund nearly 450 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. In 2013, 100 percent of funds raised by the ADDF went directly to Alzheimer's drug research and other related programs. For more information, please visit www.AlzDiscovery.org.
OnDeckBiotech is a Boston-based software company that provides software tools for biotech, pharma and R&D service vendors. The OnDeck team previously launched the MassBio Gateway, a portal to facilitate connections for the New England cluster, and will be launching BIO BizLink in collaboration with the Biotechnology Industry Organization (BIO) at this year's BIO international Convention. For more information, please visit https://www.ondeckbiotech.com/.
SOURCE Alzheimer's Drug Discovery Foundation